RDS Closes €3M Seed Funding Round

RDS, a Strasbourg, France-based developed a connected strip that facilitates the monitoring of patients at risk of post-surgical complications, raised €3M seed funding.

Backers included private and institutional investors from Europe, the USA, and Asia. Almost €1m in non-dilutive public funding was also secured with the support of Bpifrance and Région Grand Est, accelerated by the selection of RDS in July 2020 as a winner of the prestigious national i-Lab competition. RDS also benefits from the support from the French Ministry of the Armed Forces, through the Defense Innovation Agency, as part of the call for tenders launched in March 2020 for innovative solutions to combat COVID-19.

The company will use the funds to continue to expand its development efforts.

Founded in February 2020, RDS is advancing MultiSense, a connected strip equipped with five sensors (respiration, skin temperature, electrocardiogram, photoplethysmography, and accelerometer) which provide real-time medical-grade readings for a dozen cardio-respiratory vital signs. When this device becomes commercially available, it will facilitate safer monitoring of patients at risk of post-operational complications. This will accelerate the return of patients to their homes while benefitting from hospital-grade monitoring.

The strip is attached to the torso of the patient, who is also given a smartphone connected to the device via Bluetooth. This allows doctors and nurses to constantly view the patient’s vital signs through a dedicated web app. The medical team can then monitor any change in the measured parameters in real time, 24 hours a day. The strip is water-resistant (if not completely immersed), and has a battery life of five days or more thanks to a small integrated battery that can be replaced if needed.

In partnership with IHU Strasbourg, RDS received permission from ANSM (a French national agency responsible for assessing the health risks of medical products and devices) to carry out the first clinical trials before marketing the device.